Our Legacy
In the 1980s, Professor Anita Harding transformed the future of neurology at Queen Square.
At a time when clinical practice was largely limited to symptom management, she recognised that the underlying causes of neurological disease could only be further understood through the study of human genetics.
​
Through her pioneering work, Anita Harding introduced molecular genetics into clinical neurology, identifying the genetic basis of numerous neuromuscular and neurodegenerative disorders. Her groundbreaking research established Neurogenetics as a distinct scientific discipline and positioned Queen Square at the forefront of this emerging field.
​
The Neurogenetics Lab at UCL Queen Square is proud to build upon this remarkable legacy. By applying advanced genomic technologies including short and long-read sequencing and by forging global collaborations, we are committed to uncovering new disease genes, elucidating pathogenic mechanisms, and translating discoveries into improved diagnosis and care.
Guided by Professor Anita Harding’s vision of innovation, rigor, and patient-centered science, we continue to advance a more comprehensive and equitable understanding of neurological disease worldwide.
Professor Anita Harding, Pioneer of Neurogenetics at Queen Square
About the Neurogenetics Lab ION
At the Neurogenetics Lab, UCL Queen Square Institute of Neurology, we are dedicated to uncovering the genetic and molecular underpinnings of complex neurological and neurodevelopmental conditions. Our work spans a wide spectrum of disorders, including Parkinson’s disease, amyotrophic lateral sclerosis (ALS), ataxias, movement disorders, developmental and epileptic encephalopathies, and a broad range of rare and undiagnosed neurodevelopmental diseases.
​
We integrate genomic technologies including both short-read and long-read sequencing platforms with advanced analysis to identify novel disease-causing genes and to unravel the mechanisms driving disease. Our focus on multi-ethnic, globally representative populations ensures that we contribute to a more equitable and holistic understanding of the genetic architecture of neurological disease.
​
Through this integrative and inclusive approach, we aim to accelerate the path toward precision medicine, paving the way for targeted therapies and interventions that can meaningfully improve diagnosis, care, and outcomes for patients and their families around the world.
